Life Sciences IPOs and the Road Ahead

Navigating the Reopening of Capital Markets

March 3, 2025 | 8:00 am – 10:00 am

155 Seaport Boulevard, Boston, MA

The life sciences IPO market has faced significant headwinds in recent years, but signs of a potential reopening in the capital markets are emerging. As investor sentiment shifts and regulatory landscapes evolve, biotech and healthcare companies must be strategic in their approach to going public. We’ll bring together industry experts to discuss the latest trends, key considerations for IPO readiness,
and what it takes to successfully access public markets in today’s environment.

This year, we’re thrilled to welcome Stacie Aarestad, Partner at Foley Hoag; Eric Dimise, Sector Lead, Healthcare & Life Sciences, NYSE; Griffin Ehlen, Director, Investment Banking, Craig-Hallum Capital Group; Paul Gudonis, CEO, Myomo; and Rebecca Stevenson, Head of Healthcare Investment Banking, HSBC. The discussion will be moderated by Dan Giampietro, Senior Advisor of Life Science at The Baldwin Group. Gain valuable perspectives from these industry leaders as they share their predictions and strategies for the year ahead.

Following the panel, join us for a lively, moderated Q&A session, where your questions and insights will enrich the conversation.

We look forward to seeing you at this dynamic and thought-provoking event!

MODERATOR

Dan Giampietro, Senior Advisor of Life Science
The Baldwin Group

Dan specializes in developing insurance programs tailored for life science and technology organizations, as well as the venture firms that invest in them. Given the complex risk profiles and unique insurance needs of these companies, his expertise ensures comprehensive and strategic coverage solutions.

Stacie Aarestad, Partner, Co-Chair Capital Markets
Foley Hoag

Stacie is the co-chair of Foley Hoag’s Public Companies and Capital Markets practices. She specializes in corporate and securities law matters, representing issuers in a broad range of capital market transactions, and serves as outside general counsel to public companies across industries with a focus on life sciences companies.

Eric Dimise, Sector Lead, Healthcare & Life Sciences Capital Markets
NYSE

Eric is the Sector Lead for Healthcare and Life Sciences Capital Markets at NYSE Group, part of Intercontinental Exchange, Inc. (NYSE: ICE). In this role, he is responsible for attracting new listings from healthcare and life sciences companies. He also advises companies, private equity and venture capital firms, investment bankers, and other key stakeholders on the IPO landscape, NYSE initiatives, and selecting the most suitable listing venue.

Griffin Ehlen, Director, Investment Banking
Craig-Hallum Capital Groups

Griffin joined Craig-Hallum in 2020 and has extensive investment banking experience in the capital markets across various sectors. Griffin has executed over 100 equity & debt offerings and completed numerous M&A advisory transactions.

Paul Gudonis, CEO
Myomo

Paul has served as CEO of Myomo since 2011, positioning the company as a leader in medical robotics for overcoming upper limb paralysis. Under his leadership, Myomo launched its IPO in 2017 and completed multiple follow-on financings. With a 40-year career spanning biomedical devices, robotics, software, and telecommunications, Paul has pioneered new technologies and created new markets.

Rebecca Stevenson, Head of Healthcare Investment Banking Americas
HSBC

Rebecca is the Head of Healthcare Investment Banking for the Americas at HSBC. Previously, she was a Managing Director on the Biopharma Investment Banking team within Wells Fargo’s Healthcare Corporate & Investment Banking group, where she advised biopharma companies on long-term strategic financing, M&A, partnerships, and business development strategies.